Candesartan cilexetil
Atacand, Candesartan Cilexetil (candesartan cilexetil) is a small molecule pharmaceutical. Candesartan cilexetil was first approved as Atacand on 1998-06-04. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Atacand (generic drugs available since 2012-12-04)
CombinationsAtacand (generic drugs available since 2012-12-04)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atacand | New Drug Application | 2020-06-19 |
| atacand hct | New Drug Application | 2020-05-07 |
| candesartan | ANDA | 2022-12-28 |
| candesartan cilexetil | NDA authorized generic | 2023-12-15 |
| candesartan cilexetil and hydrochlorothiazide | NDA authorized generic | 2023-09-05 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA06: Candesartan
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA06: Candesartan and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DB07: Candesartan and amlodipine
— C09DX: Angiotensin ii receptor blockers (arbs), other combinations
— C09DX06: Candesartan, amlodipine and hydrochlorothiazide
HCPCS
No data
Clinical
Clinical Trials
195 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 14 | 5 | 20 | 25 | 17 | 81 |
| Essential hypertension | D000075222 | — | I10 | 2 | 6 | 3 | 2 | 3 | 16 |
| Healthy volunteers/patients | — | — | — | 11 | — | — | 1 | 2 | 14 |
| Heart failure | D006333 | HP_0001635 | I50 | — | 1 | 6 | 5 | 2 | 14 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | — | 4 | 3 | 3 | 11 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 3 | 2 | 1 | 7 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | 4 | 1 | 6 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | 5 | — | 6 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 2 | 2 | — | 5 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | — | 2 | 2 | 5 |
Show 22 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | 1 | 3 |
| Aortic valve stenosis | D001024 | HP_0001650 | — | — | — | 2 | — | — | 2 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 2 | — | — | 2 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 2 | — | — | 2 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | 1 | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | — | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | 1 | — | — | 1 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | 1 | 1 | — | — | 1 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | 1 | 1 | — | — | 1 |
| Renovascular hypertension | D006978 | EFO_1001153 | I15.0 | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 3 | — | — | — | 3 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | 1 | 2 |
| Pheochromocytoma | D010673 | — | — | — | 1 | — | — | — | 1 |
| Peripheral nervous system diseases | D010523 | HP_0009830 | G64 | — | 1 | — | — | — | 1 |
| Cocaine-related disorders | D019970 | — | F14 | — | 1 | — | — | — | 1 |
| Cardio-renal syndrome | D059347 | — | — | 1 | 1 | — | — | — | 1 |
| Alcoholic liver diseases | D008108 | EFO_0008573 | K70 | 1 | 1 | — | — | — | 1 |
| Hepatitis c | D006526 | — | B19.2 | — | 1 | — | — | — | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 1 | — | — | — | 1 |
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Barrett esophagus | D001471 | EFO_0000280 | K22.7 | 1 | — | — | — | — | 1 |
| Hyperphosphatemia | D054559 | HP_0002905 | — | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | — | 2 | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 2 | 2 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | — | — | 1 | 1 |
| Frailty | D000073496 | — | R53.1 | — | — | — | — | 1 | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 1 | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 1 | 1 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | — | 1 | 1 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | — | — | — | 1 | 1 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | — | 1 | 1 |
| Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Candesartan cilexetil |
| INN | — |
| Description | Candesartan is a benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension. It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an environmental contaminant and a xenobiotic. It is a benzimidazolecarboxylic acid and a biphenylyltetrazole. It is a conjugate acid of a candesartan(2-). |
| Classification | Small molecule |
| Drug class | angiotensin II receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 139481-59-7 |
| RxCUI | 214354 |
| ChEMBL ID | CHEMBL1014 |
| ChEBI ID | 3348 |
| PubChem CID | 2541 |
| DrugBank | DB13919 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Atacand – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,206 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atacand, Atacand hct, Candesartan, Candesartan cilexetil, Candesartan cilexetil and hydrochlorothiazide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17,317 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use